Aytu BioPharma (AYTU) 10-Q 11 May 16 2016 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Mar. 31, 2016	May. 06, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Entity Registrant Name	AYTU BIOSCIENCE, INC
Entity Central Index Key	1,385,818
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Trading Symbol	AYTU
Entity Common Stock, Shares Outstanding		44,856,459

Balance Sheets

Balance Sheets - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Current assets
Cash and cash equivalents	$ 8,665,835	$ 7,353,061
Accounts receivable, net	84,274	157,058
Inventory	621,352	39,442
Prepaid expenses and other	943,126	370,888
Prepaid research and development - related party (Note 11)	121,983	121,983
Total current assets	10,436,570	8,042,432
Fixed assets, net	196,885	29,706
Developed technology, net	1,201,153	780,125
Customer contracts, net	1,405,125	711,000
Trade names, net	202,306	79,000
Goodwill	221,000	74,000
In-process research and development	7,500,000	7,500,000
Patents, net	575,686	628,776
Long-term portion of prepaid research and development - related party (Note 11)	243,967	335,454
Deposits	2,888	4,886
Total non current assets	11,549,010	10,142,947
Total assets	21,985,580	18,185,379
Current liabilities
Accounts payable and accrued liabilities	1,177,049	1,195,368
Primsol payable	1,154,616	0
Accrued compensation	787,954	196,503
Deferred revenue	85,714	85,714
Total current liabilities	3,205,333	1,477,585
Convertible promissory notes, net of amortization discount of $1,040,203 (Note 8)	9,797	0
Contingent consideration	698,826	664,000
Long-term deferred revenue	361,607	425,893
Interest payable	66,131	0
Deferred rent	12,009	1,449
Warrant derivative liability	66,204	0
Total liabilities	$ 4,419,907	$ 2,568,927
Commitments and contingencies (Note 7)
Stockholders' equity
Preferred Stock, par value $.0001; 50,000,000 shares authorized; none issued	$ 0	$ 0
Common Stock, par value $.0001; 300,000,000 shares authorized; shares issued and outstanding 22,446,481 (unaudited) and 14,259,681, respectively as of March 31, 2016 and June 30, 2015	2,245	1,426
Additional paid-in capital	48,827,395	38,996,367
Ampio stock subscription	0	(5,000,000)
Accumulated deficit	(31,263,967)	(18,381,341)
Total stockholders' equity	17,565,673	15,616,452
Total liabilities and stockholders' equity	$ 21,985,580	$ 18,185,379

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, authorized shares	50,000,000	50,000,000
Preferred stock, issued shares	0	0
Common Stock, par value	$ 0.0001	$ 0.0001
Common stock, authorized shares	300,000,000	300,000,000
Common stock, issued shares	22,446,481	14,259,681
Common stock, outstanding shares	22,446,481	14,259,681
Convertible Notes Payable [Member]
Convertible promissory notes, amortization discount	$ 1,040,203

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Product and service revenue	$ 647,112	$ 2,400	$ 1,560,854	$ 15,460
License revenue	21,429	21,429	64,286	64,286
Total revenue	668,541	23,829	1,625,140	79,746
Operating expenses
Cost of sales	340,796	0	622,222	0
Research and development	1,143,676	694,180	3,308,009	2,418,125
Research and development - related party (Note 11)	47,998	47,998	143,994	155,994
Sales, general and administrative	2,244,747	1,070,091	5,670,718	2,933,506
Amortization of finite-lived intangible assets	118,697	17,697	284,633	53,091
Total operating expenses	3,895,914	1,829,966	10,029,576	5,560,716
Loss from operations	(3,227,373)	(1,806,137)	(8,404,436)	(5,480,970)
Other (expense) income
Interest (expense)	(4,074,668)	(36,052)	(4,428,136)	(110,900)
Derivative income (expense)	27,983	0	(50,054)	0
Total other (expense)	(4,046,685)	(36,052)	(4,478,190)	(110,900)
Net loss, before income tax	(7,274,058)	(1,842,189)	(12,882,626)	(5,591,870)
Deferred income tax benefit	0	0	0	23,910
Net loss	$ (7,274,058)	$ (1,842,189)	$ (12,882,626)	$ (5,567,960)
Weighted average number of Aytu common shares outstanding (in shares)	18,828,934	7,901,426	15,771,692	7,901,426
Basic and diluted Aytu net loss per common share (in dollars per share)	$ (0.39)	$ (0.23)	$ (0.82)	$ (0.70)

Statement of Stockholders' Equi

Statement of Stockholders' Equity - 9 months ended Mar. 31, 2016 - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Ampio Stock Subscription [Member]	Accumulated Deficit [Member]
Balance at Jun. 30, 2015	$ 15,616,452	$ 1,426	$ 38,996,367	$ (5,000,000)	$ (18,381,341)
Balance (in shares) at Jun. 30, 2015		14,259,681
Adjustment for rounding of shares due to conversion (unaudited)	0	$ 0	0	0	0
Adjustment for rounding of shares due to conversion (in shares)		12
Ampio stock subscription (unaudited)	5,000,000	$ 0	0	5,000,000	0
Stock subscription (unaudited)	200,000	$ 31	199,969	0	0
Stock subscription (unaudited) (in shares)		307,692
Conversion of convertible promissory notes to common stock, net of $29,754 conversion costs (unaudited)	8,997,957	$ 788	8,997,169	0	0
Conversion of convertible promissory notes to common stock, net of $29,754 conversion costs (unaudited) (in shares)		7,879,096
Stock-based compensation (unaudited)	547,109	$ 0	547,109	0	0
Stock-based compensation (in shares)		0
Net loss (unaudited)	(12,882,626)	$ 0	0	0	(12,882,626)
Issuance of warrants related to the convertible promissory notes (unaudited)	87,000	0	86,781	0	0
Balance at Mar. 31, 2016	$ 17,565,673	$ 2,245	$ 48,827,395	$ 0	$ (31,263,967)
Balance (in shares) at Mar. 31, 2016		22,446,481

Convertible Promissory Notes (A

Convertible Promissory Notes (Additional Information)	9 Months Ended
	Mar. 31, 2016USD ($)
Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs	$ 29,754

Statements of Cash Flows

Statements of Cash Flows - USD ($)	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities
Net loss	$ (12,882,626)	$ (5,567,960)
Stock-based compensation expense	547,109	749,810
Depreciation, amortization and accretion	433,471	73,746
Amortization of debt issuance costs	178,338	0
Amortization of beneficial conversion feature	3,942,613	0
Derivative expense	50,054	0
Amortization of prepaid research and development - related party (Note 11)	91,487	91,488
Deferred taxes	0	(23,910)
Adjustments to reconcile net loss to net cash used in operating activities:
Decrease (increase) in accounts receivable	72,784	(1,036)
(Increase) in inventory	(581,910)	(11,233)
(Increase) decrease in prepaid expenses and other	(572,238)	496,322
(Increase) in prepaid research and development - related party (Note 11)	0	(150,000)
(Decrease) in accounts payable and accrued liabilities	(18,319)	(103,158)
(Decrease) in related party payable	0	(392,509)
Increase in accrued compensation	591,451	98,949
Increase (decrease) in interest payable	208,941	(42,673)
Increase in deferred rent	10,560	0
(Decrease) in deferred revenue	(64,286)	(64,286)
Net cash used in operating activities	(7,992,571)	(4,846,450)
Cash flows used in investing activities
Deposits	1,998	(1,998)
Purchases of fixed assets	(203,577)	0
Purchase of Primsol business	(540,000)	0
Net cash used in investing activities	(741,579)	(1,998)
Cash flows from financing activities
Proceeds from convertible note from Ampio converted to stock	0	3,700,000
Proceeds from convertible promissory notes, net (Note 8)	5,175,000	0
Debt issuance costs (Note 8)	(298,322)	0
Ampio stock subscription payment	5,000,000	0
Sale of stock subscription	200,000	0
Costs related to the conversion of the convertible promissory notes to equity	(29,754)	0
Net cash provided by financing activities	10,046,924	3,700,000
Net change in cash and cash equivalents	1,312,774	(1,148,448)
Cash and cash equivalents at beginning of period	7,353,061	2,639,650
Cash and cash equivalents at end of period	8,665,835	1,491,202
Non-cash transactions:
Warrant derivative liability related to the issuance of the convertible promissory notes (Note 8)	102,931	0
Primsol business purchase included in primsol payable, $1,250,000 less future accretion of $173,000	1,077,000	0
Conversion of convertible promissory notes and interest of $143,000 to common stock	4,268,000	0
Reclassification of liability based warrants to equity presentation related to the convertible promissory notes	87,000	0
Beneficial conversion feature of $4,943,073 less $3,942,613 of accretion related to unconverted convertible promissory notes	1,001,000	0
Debt issuance costs related to notes that converted to equity	$ (183,000)	$ 0

Statements of Cash Flows (Paren

Statements of Cash Flows (Parenthetical) - USD ($)	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Primsol Business Purchase Included In Primsol Payable Gross	$ 1,250,000	$ 1,250,000
Accretion of Discount	$ 173,000	$ 173,000
Conversion of Stock, Shares Issued	143,000	143,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 4,943,073	$ 4,943,073
Accretion Expense	$ 3,942,613	$ 3,942,613

Business, Acquisition of Assets

Business, Acquisition of Assets and Basis of Presentation	9 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Business Description and Basis of Presentation [Text Block]	Note 1 – Business, Acquisition of Assets and Basis of Presentation Business/Acquisition of Assets Aytu BioScience, Inc. (“Aytu” or the “Company”) was incorporated as Rosewind Corporation on August 9, 2002 in the State of Colorado. Aytu was re-incorporated in the state of Delaware on June 8, 2015. Aytu is a specialty healthcare company concentrating on acquiring, developing and commercializing products focused primarily on the urological disorders market, specifically sexual dysfunction, urological cancer, urinary tract infections and male infertility. Basis of Presentation These unaudited financial statements represent the financial statements of Aytu. These unaudited financial statements should be read in conjunction with Aytu’s Annual Report on Form 10-K for the year ended June 30, 2015, which included all disclosures required by generally accepted accounting principles (“GAAP”). In the opinion of management, these unaudited financial statements contain all adjustments necessary to present fairly the financial position of Aytu for the balance sheet and the results of operations and cash flows for the interim periods presented. The results of operations for the period ended March 31, 2016 are not necessarily indicative of expected operating results for the full year. The information presented throughout this report as of and for the period ended March 31, 2016 is unaudited. Aytu’s current business was formed through a reverse triangular merger (the “Merger”) in which Luoxis Diagnostics, Inc. (“Luoxis”) and Vyrix Pharmaceuticals, Inc. (“Vyrix”) merged into Rosewind Corporation in a multi-step merger on April 16, 2015. These historical financial statements prior to April 16, 2015 include the combined financial statements of Vyrix from its inception in November 2013, combined with the carve-out financial statements related to Vyrix assets acquired in the Merger (the “Vyrix Acquired Assets”) from March 23, 2011, the date its parent company, Ampio Pharmaceuticals, Inc. (“Ampio”), originally acquired the Vyrix Acquired Assets through its merger with DMI BioSciences, Inc. (“BioSciences”) and the financial statements of Luoxis from its inception in January 2013, combined with the carve-out financial statements related to Luoxis. On June 8, 2015, in connection with the reincorporation as a Delaware corporation, the Company effected a reverse stock split in which each common stock holder received one share of common stock for every 12.174 shares then outstanding (the “Reverse Stock Split”). All share and per share amounts in this Report have been adjusted to reflect the effect of the Reverse Stock Split. Business Combination—ProstaScint In May 2015, Aytu entered into and closed on an asset purchase agreement with Jazz Pharmaceuticals, Inc. (the “Seller”). Pursuant to the agreement, Aytu purchased assets related to the Seller’s product known as ProstaScint® (capromab pendetide), including certain intellectual property and contracts, and the product approvals, inventory and work in progress (together, the “ProstaScint Business”), and assumed certain of the Seller’s liabilities, including those related to product approvals and the sale and marketing of ProstaScint. The purchase price consisted of the upfront payment of $1.0 million. Aytu also paid an additional $500,000 for the ProstaScint-related product inventory and $227,000 (which represents a portion of certain FDA fees). Aytu also will pay 8% as contingent consideration on its net sales made after October 31, 2017, payable up to a maximum aggregate payment of an additional $2.5 million. The contingent consideration was valued at $664,000 using a discounted cash flow estimate as of the acquisition date. The total fair value consideration for the purchase was $2.4 million. The Company’s allocation on consideration transferred for ProstaScint as of the purchase date of May 20, 2015 is as follows: Fair Value Tangible assets $ 727,000 Intangible assets 1,590,000 Goodwill 74,000 Total assets acquired $ 2,391,000 Included in the intangible assets is developed technology of $790,000, customer contracts of $720,000 and trade names of $80,000, each of which will be amortized over a ten-year period. As of March 31, 2016 the contingent consideration had increased to $699,000 due to accretion. Business Combination—Primsol In October 2015, Aytu entered into and closed on an Asset Purchase Agreement with FSC Laboratories, Inc. (the “Seller”). Pursuant to the agreement, Aytu purchased assets related to the Seller’s product known as Primsol® (trimethoprim solution), including certain intellectual property and contracts, inventory, work in progress and all marketing and sales assets and materials related solely to Primsol (together, the “Primsol Business”), and assumed certain of the Seller’s liabilities, including those related to the sale and marketing of Primsol arising after the closing. Aytu paid $500,000 at closing for the purchase of the Primsol Business and paid an additional $142,000, of which $102,000 went to inventory and $40,000 towards the Primsol Business, for the transfer of the Primsol-related product inventory. We also agreed to pay an additional (a) $500,000 which was paid on April 1, 2016, (b) $500,000 payable no later than June 30, 2016, and (c) $250,000 payable no later than September 30, 2016 (together, the “Installment Payments”). The Company’s allocation on consideration transferred for Primsol as of the purchase date of October 5, 2015 is as follows: Fair Value Tangible assets $ 182,000 Intangible assets 1,470,000 Goodwill 147,000 Total assets acquired $ 1,799,000 Included in tangible assets is $102,000 of inventory and $80,000 of work-in-process inventory. Included in the intangible assets is developed technology of $520,000, customer contracts of $810,000 and trade names of $140,000, each of which will be amortized over a six-year period. As of March 31, 2016, the accrued payable adjusted for the present value was $1,155,000. Adoption of Newly Issued Accounting Pronouncements In September 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-16, “Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments,” which requires that an acquirer recognize adjustments to estimated amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments require that the acquirer record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the estimated amounts, calculated as if the accounting had been completed at the acquisition date. The amendments also require an entity to present separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the estimated amounts had been recognized as of the acquisition date. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2015 and early adoption is permitted. As of March 31, 2016, the Company has early adopted this standard. In April 2015, the FASB issued ASU 2015-03, “Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs” to simplify the presentation of debt issuance costs. The amendments in the update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct reduction of the carrying amount of the debt. Recognition and measurement of debt issuance costs were not affected by this amendment. In August 2015, FASB issued ASU 2015-15, “Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements — Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting” which clarified that the SEC would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement. The amendments are effective for financial statements issued for fiscal years beginning after December 15, 2015. During the quarter ended September 30, 2016, the Company early adopted this standard and recorded debt issuance costs as a debt discount. There was no impact related to this adoption as the Company did not have any debt issuance costs prior to adoption. In November 2015, the FASB issued ASU No. 2015-17 regarding ASC Topic 470 "Income Taxes: Balance Sheet Classification of Deferred Taxes." The amendments in ASU 2015-17 eliminate the requirement to bifurcate deferred taxes between current and non-current on the balance sheet and requires that deferred tax liabilities and assets be classified as noncurrent on the balance sheet. The amendments for ASU-2015-17 can be applied retrospectively or prospectively and early adoption is permitted. Aytu early adopted ASU 2015-17 and there was no material impact on its financial statements. Recently Issued Accounting Pronouncements, Not Adopted as of March 31, 2016 In March 2016, the FASB issued Accounting Standards Update No. 2016-09, “Compensation –Stock Compensation (Topic 718): Improvements to Employee Share Based Payment Accounting”. The standard includes multiple provisions intended to simplify various aspects of the accounting for share based payments. The amendments are expected to significantly impact net income, EPS, and the statement of cash flows. Implementation and administration may present challenges to companies with significant share based payment activities. The amendments are effective for public entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. The Company is currently evaluating the impact of this standard on its financial statements. In February 2016, the FASB issued Accounting Standards Update 2016-02, “Leases (Topic 842)”. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact of its pending adoption of this standard on its financial statements. In January 2016, the FASB issued ASU 2016-01, “Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities,” which requires that all equity investments be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under the equity method of accounting or those that result in consolidation of the investee). The amendments in this update also require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. In addition, the amendments in this update eliminate the requirement to disclose the fair value of financial instruments measured at amortized cost for entities that are not public business entities and the requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet for public business entities. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2017. Early adoption is not permitted. The Company is currently evaluating the impact of this standard on its financial statements. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” ASU 2015-11 clarifies that inventory should be held at the lower of cost or net realizable value. Net realizable value is defined as the estimated selling price, less the estimated costs to complete, dispose and transport such inventory. ASU 2015-11 will be effective for fiscal years and interim periods beginning after December 15, 2016. ASU 2015-11 is required to be applied prospectively and early adoption is permitted. The adoption of ASU 2015-11 is not expected to have a material impact on the Company’s financial position or results of operations. In August 2014, the FASB issued ASU 2014-15, “Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods ending after December 15, 2016, with early adoption permitted. The Company is evaluating the impact the adoption of ASU 2014-15 will have on its financial statements. In May 2014, the FASB issued ASU 2014-09 regarding ASC Topic 606, “Revenue from Contracts with Customers”. The standard provides principles for recognizing revenue for the transfer of promised goods or services to customers with the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date, which deferred the effective date of the new revenue standard for periods beginning after December 15, 2017, with early adoption permitted. In March 2016, the FASB issued ASU 2016-08, which addresses principal versus agent considerations. The Company is currently evaluating the effect that the updated standard will have on its financial statements.

Fixed Assets

Fixed Assets	9 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Note 2 – Fixed Assets Fixed assets are recorded at cost and, once placed in service, are depreciated on the straight-line method over the estimated useful lives. Estimated As of March 31, As of June 30, Useful Lives in years 2016 2015 Office equipment and furniture 3 - 5 $ 154,000 $ - Lab equipment 3 - 5 90,000 90,000 Leasehold improvements 3 43,000 - Manufacturing equipment 5 7,000 - Less accumulated depreciation and amortization (97,000) (60,000) Fixed assets, net $ 197,000 $ 30,000

In-Process Research and Develop

In-Process Research and Development	9 Months Ended
	Mar. 31, 2016
Research and Development [Abstract]
Research, Development, and Computer Software Disclosure [Text Block]	Note 3 – In-Process Research and Development In-process research and development (“IPRD”) relates to the Zertane product candidate. The $ 7.5

Patents

Patents	9 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	Note 4 – Patents Costs of establishing patents, consisting of legal and filing fees paid to third parties, are expensed as incurred. The fair value of the Zertane patents, determined by an independent, third party appraisal to be $ 500,000 11 380,000 15 As of As of March 31, June 30, 2016 2015 Patents $ 880,000 $ 880,000 Less accumulated amortization (304,000) (251,000) Patents, net $ 576,000 $ 629,000

Revenue Recognition

Revenue Recognition	9 Months Ended
	Mar. 31, 2016
Revenue Recognition [Abstract]
Revenue Recognition And License Agreement [Text Block]	Note 5 – Revenue Recognition The $ 647,000 2,000 1,561,000 15,000 The license revenue of $ 21,000 64,000 500,000 250,000

Fair Value Considerations

Fair Value Considerations	9 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Consideration [Text Block]	Note 6 – Fair Value Considerations Aytu’s financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, convertible promissory notes and warrant derivative liability. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. The fair value of the convertible notes was approximately the face value of the notes (see Note 8 for more information). The valuation policies are determined by the Chief Financial Officer and approved by the Company’s Board of Directors. Authoritative guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of Aytu. Unobservable inputs are inputs that reflect Aytu’s assumptions of what market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows: Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities; Level 2: Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and Level 3: Unobservable inputs that are supported by little or no market activity. Aytu’s assets and liabilities which are measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Aytu’s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. Aytu has consistently applied the valuation techniques discussed below in all periods presented. Fair Value Measurements Using Level 1 Level 2 Level 3 Total March 31, 2016 LIABILITIES Warrant derivative liability $ - $ - $ 66,000 $ 66,000 The warrant derivative liability for the warrants was valued using the Monte Carlo valuation methodology because that model embodies all of the relevant assumptions that address the features underlying these instruments. March 31, 2016 At Issuance Warrants: Exercise price $ 0.64 $ 1.51 - $1.95 Volatility 75.0 % 75.0 % Equivalent term (years) 4.31 - 4.36 5.0 - 5.11 Risk-free interest rate 1.09% - 1.10 % 1.54% - 1.74 % Potential number of shares 159,000 - 228,000 139,000 - 224,000 Derivative Instruments Balance as of June 30, 2015 $ - Warrant issuances 103,000 Reclassification of warrant liability to equity upon note conversion (87,000) Change in fair value included in earnings 50,000 Balance as of March 31, 2016 $ 66,000

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 7 – Commitments and Contingencies Remaining Total 2016 2017 2018 2019 2020 Thereafter Management fee $ 901,000 $ 53,000 $ 212,000 $ 212,000 $ 212,000 $ 212,000 $ - Primsol business 1,250,000 1,000,000 250,000 - - - - Manufacturing agreement 1,000,000 1,000,000 - - - - - Office Lease 351,000 34,000 142,000 145,000 30,000 - - Sponsored research agreement with related party 298,000 18,000 70,000 70,000 70,000 70,000 - $ 3,800,000 $ 2,105,000 $ 674,000 $ 427,000 $ 312,000 $ 282,000 $ - Management Fee In July 2015, Aytu entered into an agreement with Ampio whereby Aytu agreed to pay Ampio a set amount per month for shared overhead which includes costs related to the shared facility, corporate staff, and other miscellaneous overhead expenses. This agreement was amended on November of 2015 and again in April of 2016 resulting in an amount of $ 18,000 Primsol Business In October 2015, Aytu entered into an agreement with FSC Laboratories, Inc. for the purchase of Primsol (see Note 1). Manufacturing Agreement In October 2015, Aytu entered into a Master Services Agreement with Biovest International, Inc. (“Biovest”). The agreement provides that Aytu may engage Biovest from time to time to provide services in accordance with mutually agreed upon project addendums and purchase orders. Aytu expects to use the agreement from time to time for manufacturing services, including without limitation, the manufacturing, processing, quality control testing, release or storage of its products for the ProstaScint product. Aytu is obligated to pay Biovest $ 1.0 500,000 Office Lease In June 2015, Aytu entered into a 37 3,000 112,000 37 9,000 318,000 Three Months Ended March 31, Nine Months Ended March 31, 2016 2015 2016 2015 Rent expense $ 35,000 $ 3,000 $ 86,000 $ 43,000 Sponsored Research Agreement with Related Party Aytu entered into a Sponsored Research Agreement with Trauma Research LLC (“TRLLC”), a related party, in June 2013. Under the terms of the Sponsored Research Agreement, TRLLC agreed to work collaboratively in advancing the RedoxSYS System diagnostic platform through research and development efforts. The Sponsored Research Agreement may be terminated without cause by either party on 30

Convertible Promissory Notes

Convertible Promissory Notes	9 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 8 – Convertible Promissory Notes Convertible Promissory Notes During July and August 2015, Aytu closed on note purchase agreements with institutional and high net worth individual investors for the purchase and sale of convertible promissory notes (“Notes”) with an aggregate principal amount of $ 5.2 401,000 103,000 The Notes are an unsecured obligation. Unless earlier converted, the Notes will mature 18 2 8 12 The Notes are convertible at any time at the noteholder’s discretion into that number of shares of Aytu common stock equal to 120 4.63 5.0 Placement agents for the offerings sold the institutional portion of the offering of the Notes. Aytu sold the balance of the Notes to individuals and entities with whom Aytu has an established relationship. For Notes sold by the placement agent, Aytu paid the placement agent 8 20,000 The warrants were recorded at fair value as long-term liabilities on the Balance Sheet (see Note 6). Upon Aytu’s adoption of ASU 2015-3, the costs associated with the Notes were recorded as a long–term liability and are presented in the Balance Sheet as a direct reduction of the carrying amount of the Notes on their inception date. Per the convertible promissory note agreements, if Aytu sells equity securities at any time while the notes are outstanding in a financing transaction that is not a Qualified Financing, the holders of the convertible promissory notes have the option, but not the obligation, to convert the outstanding principal and accrued interest as of the as of the closing of such financings into a number of shares of Aytu capital stock in an amount equal to 120% of the number of such shares calculated by dividing the outstanding principal and accrued interest by the lesser of (a) the lowest cash price per share paid by purchasers of shares in such financing, or (b) $4.63. As a result of Aytu’s sale of common stock on January 20, 2016, the Company was obligated to provide notice to the above-referenced noteholders of such stock sales. In accordance with the convertible note terms, for a period of ten business days (which was extended to 15 business days by the Company, or February 10, 2016) following receipt of the notice, noteholders had the option to convert their entire balance (inclusive of accrued but unpaid interest) into a number of shares of Aytu common stock equal to 120% of the number of shares calculated by dividing such note balance by $ 0.65 4,125,000 143,000 7,879,096 1,050,000 66,000 In connection with the conversion of the Aytu notes, Aytu was obligated to issue to the placement agents for the convertible note offering warrants for an amount of shares equal to 8% of the number of shares of Aytu’s common stock for the notes sold by the placement agents issued upon conversion of the notes. As a result of the optional note conversion, on February 10, 2016, Aytu issued warrants to the placement agents to purchase an aggregate of 267,052 0.65 Also in connection with the conversion of the notes, Aytu recorded a beneficial conversion feature of $ 3.9 As of March 31, 2016, the carrying value of the notes was $ 10,000 1,040,000 A majority of the remaining noteholders have signed lock-up agreements, which prohibit them from selling their stock until July 5, 2016. These noteholders received a 10

Common Stock

Common Stock	9 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 9 – Common Stock Capital Stock At March 31, 2016 and June 30, 2015, Aytu had 22,446,481 14,259,681 300 0.0001 50 0.0001 The Board of the Company had proposed the reverse stock split in an effort to decrease the number of shares of common stock outstanding and increase the market price of its shares. The Board is also seeking to reduce certain administrative burdens and costs relating to the large number of shares that are currently issued and outstanding. The Board is asking its stockholders to approve a reverse split of the common stock and grant to the Board the authority to set the ratio for the reverse split in the range of 1-for-4 and 1-for-12 or not to complete the reverse stock split, as determined in the discretion of the Board at any time before November 24, 2016. The Board believes that the reverse stock split will enhance the Company’s ability to obtain an initial listing on a national securities exchange. This proposal will be voted on by the Company’s shareholders at the annual shareholders meeting on May 24, 2016. The Board of Directors has approved and recommended a proposal to amend the Company’s Certificate of Incorporation, to reduce the authorized shares of common stock from 300,000,000 to 100,000,000 10,000,000

Equity Instruments

Equity Instruments	9 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 10 – Equity Instruments Options Prior to the Merger, Aytu had two approved stock option plans (Luoxis 2013 Stock Option Plan and Vyrix 2013 Stock Option Plan), pursuant to which Aytu had reserved a total of 1,718,828 The Luoxis options that were in the money and all outstanding Vyrix options issued under the respective 2013 Option Plans were accelerated and cancelled in connection with the Merger. Option holders received a cash payment per option share equal to the difference between the consideration payable per share of common stock pursuant to the Merger and the exercise price of the option; if the consideration paid to holders of common stock was less than the exercise price of such options, no amount was paid to the option holder in connection with the cancellation. The cash payment during the period ended June 30, 2015 was $ 27,000 422,000 189,000 The Luoxis options that were not paid out were terminated pursuant to the terms of the 2013 Luoxis Option Plan. The Company treated these options as pre-vesting forfeitures and $ 433,000 On June 1, 2015, Aytu’s stockholders approved the 2015 Stock Option and Incentive Plan (the “2015 Plan”), which provides for the award of stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 10.0 Expected volatility 75.00 % Risk free interest rate 1.21% - 1.90 % Expected term (years) 3.75 - 6.25 Dividend yield 0 % Weighted Weighted Average Number of Average Remaining Contractual Options Exercise Price Life in Years Outstanding June 30, 2015 - $ - Granted 3,717,500 $ 1.55 Exercised - $ - Forfeited/Cancelled (50,000) $ 1.51 Outstanding March 31, 2016 3,667,500 $ 1.55 9.55 Exercisable at March 31, 2016 1,477,500 $ 1.51 9.62 Available for grant at March 31, 2016 6,332,500 Stock-based compensation expense related to the fair value of stock options was included in the statements of operations as research and development expenses and selling, general and administrative expenses as set forth in the table below. Aytu determined the fair value as of the date of grant using the Black-Scholes option pricing model and expenses the fair value ratably over the vesting period. Three Months Ended March 31, Nine Months Ended March 31, 2016 2015 2016 2015 Research and development expenses Stock options $ 38,000 $ 115,000 $ 63,000 $ 323,000 Selling, general and administrative expenses Stock options 258,000 157,000 484,000 427,000 $ 296,000 $ 272,000 $ 547,000 $ 750,000 Unrecognized expense at March 31, 2016 $ 1,554,000 Weighted average remaining years to vest 2.90 Of the options that Aytu issued during the nine months ended March 31, 2016, 1,447,500 1.3 Warrants Aytu issued warrants in conjunction with its 2013 private placement as well as to the placement agents in conjunction with the 2015 convertible promissory note financing that converted to common stock (see Note 8). The 2015 warrants were previously classified as a liability and upon conversion of the notes to common stock the associated warrants were assigned a value and moved to equity. A summary of these warrants is as follows: Weighted Weighted Average Number of Average Remaining Contractual Warrants Exercise Price Life in Years Outstanding June 30, 2015 102,613 $ 4.53 2.92 Warrants issued to placement agents for convertible promissory notes 267,052 $ 0.65 Outstanding March 31, 2016 (unaudited) 369,665 $ 1.73 3.78 Expected volatility 75 % Risk free interest rate 1.36% - 1.37 % Contractual term (years) 4.6 Dividend yield 0 % Warrant Obligation related to the Convertible Promissory Notes Aytu has the obligation to issue warrants to the private placement agents for the 2015 convertible note financing as part of their fees for the financing. These warrants are classified as a derivative warrant liability due to the fact that the number of shares and exercise price have not been set as of March 31, 2016. The number of shares of Company stock that these warrants will convert into is equal to 8% of the gross number of shares of the Company stock issuable upon conversion of the Notes issued to investors introduced to the Company by the private placement agents pursuant to the private placement memorandum. The exercise price will be the conversion price per share at which the first outstanding Note converts into Company common stock. The warrants have a term of five years from August 31, 2015 due to the conversion setting the price of these warrants (see Note 8). 267,052 0.65 87,000

Related Party Transactions

Related Party Transactions	9 Months Ended
	Mar. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 11 – Related Party Transactions Ampio Loan Agreement In November 2013, Vyrix entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend Vyrix up to an aggregate amount of $ 3.0 500,000 1.6 3.11 3.32 4.0 In March 2014, Luoxis entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend Luoxis $ 3.0 3.0 3.11 3.32 8.0 On April 16, 2015, Ampio received 4,761,787 10.0 8.0 4.0 Services Agreement The Company has entered into a service agreement with Ampio which is described in Note 7. Sponsored Research Agreement In June 2013, Luoxis entered into a sponsored research agreement with TRLLC, an entity controlled by Ampio’s director and Chief Scientific Officer, Dr. Bar-Or. The agreement, which was amended in January 2015 and provides for Luoxis (now Aytu) to pay $ 6,000 615,000 60.5 Convertible Promissory Notes The convertible promissory notes (see Note 8) include $ 275,000

Subsequent Events

Subsequent Events	9 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 12 – Subsequent Events In April 2016, the Company added a fourth director. He will hold office until the Company’s next annual meeting of stockholders. In April, the Board granted to each of Aytu’s two non-executive directors, including the new director, options to purchase 100,000 0.56 On April 22, 2016, the Company entered into and closed a license and supply agreement for the exclusive U.S. rights to Natesto™ (testosterone) nasal gel from Acerus Pharmaceuticals Corporation (“Acerus”). The license’s term runs for the greater of eight years or until the expiry of the latest to expire patent including claims covering Natesto and until the entry on the market of at least one AB-rated generic product. Aytu paid Acerus an upfront fee of $ 2.0 2.0 4.0 In addition to the upfront payments, Aytu must make the following one-time, non-refundable payments to Acerus within 45 days of the occurrence of the following event: ⋅ $ 2.5 25.0 ⋅ $ 5.0 50.0 ⋅ $ 7.5 75.0 ⋅ $ 10.0 100.0 ⋅ $ 12.5 125.0 The Company also agreed to purchase on April 28, 2016, an aggregate of 12,245,411 2,534,800 2.0 0.207 During the term of the agreement, Aytu will purchase all of its Natesto product need from Acerus. Each month Aytu will provide Acerus with a two-year forecast of its product needs, the first three months of which will be noncancelable. Pursuant to the agreement, Aytu will pay Acerus a supply price per unit of the greater of 115% of Acerus’ cost of goods sold for Natesto, not to exceed a fixed ceiling price and (ii) 10% of the net selling price for the first year of the agreement that increases to 16% in the second year and 25% in the third year of the agreement and remains constant after that. Upon the expiration or invalidation of the last-to-expire (or be invalidated) Acerus patent covered by the agreement, the supply price will be reduced to an amount equal to the sum of (A) 115% of Acerus’ cost of goods sold (but not to exceed the fixed ceiling price) and (B) 50% of the difference between the supply price and 115% of Acerus’ cost of goods sold (but not to exceed the fixed ceiling price); provided that the supply price will not be reduced to an amount lower than 115% of Acerus’ cost of goods sold (but no to exceed the fixed ceiling price). In the event of any termination of the agreement prior to the date on which the Second Upfront, Third Upfront and/or First Milestone is otherwise payable, all of those amounts will, unless otherwise paid prior to the effective date of termination, be payable on the effective termination date. Following the termination date, any further milestone amounts will be payable to Acerus in accordance with the agreement, even if the milestone is met after the termination date. On May 2, 2016, the Company entered into an underwriting agreement with Joseph Gunnar & Co. as representative of the several underwriters named therein, relating to an underwritten public offering of 18,750,000 0.0001 18,750,000 0.40 0.50 The Company’s net proceeds from the sale of the shares was approximately $ 6.7 2,812,500 2,812,500 2,049,250 In connection with the public offering, Aytu is obligated to issue to the placement agents’ warrants for an amount of shares equal to 7 1,312,500 0.50 five Pursuant to the terms of the notes, the notes (inclusive of accrued but unpaid interest) were automatically convertible due to the public offering, into securities of the Company in an amount equal to 120 130 0.40 1,050,000 78,000 3,659,978 3,659,978 0.50 In connection with the conversion, we were obligated to issue to the placement agents for the convertible note offering warrants for an amount of shares equal to 8 270,772 0.40 After all of these transactions, the Company has 44,856,459 30,279,665 0.64

Business, Acquisition of Asse21

Business, Acquisition of Assets and Basis of Presentation (Policies)	9 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation These unaudited financial statements represent the financial statements of Aytu. These unaudited financial statements should be read in conjunction with Aytu’s Annual Report on Form 10-K for the year ended June 30, 2015, which included all disclosures required by generally accepted accounting principles (“GAAP”). In the opinion of management, these unaudited financial statements contain all adjustments necessary to present fairly the financial position of Aytu for the balance sheet and the results of operations and cash flows for the interim periods presented. The results of operations for the period ended March 31, 2016 are not necessarily indicative of expected operating results for the full year. The information presented throughout this report as of and for the period ended March 31, 2016 is unaudited. Aytu’s current business was formed through a reverse triangular merger (the “Merger”) in which Luoxis Diagnostics, Inc. (“Luoxis”) and Vyrix Pharmaceuticals, Inc. (“Vyrix”) merged into Rosewind Corporation in a multi-step merger on April 16, 2015. These historical financial statements prior to April 16, 2015 include the combined financial statements of Vyrix from its inception in November 2013, combined with the carve-out financial statements related to Vyrix assets acquired in the Merger (the “Vyrix Acquired Assets”) from March 23, 2011, the date its parent company, Ampio Pharmaceuticals, Inc. (“Ampio”), originally acquired the Vyrix Acquired Assets through its merger with DMI BioSciences, Inc. (“BioSciences”) and the financial statements of Luoxis from its inception in January 2013, combined with the carve-out financial statements related to Luoxis. On June 8, 2015, in connection with the reincorporation as a Delaware corporation, the Company effected a reverse stock split in which each common stock holder received one share of common stock for every 12.174 shares then outstanding (the “Reverse Stock Split”). All share and per share amounts in this Report have been adjusted to reflect the effect of the Reverse Stock Split.
Business Combinations Policy [Policy Text Block]	Business Combination—ProstaScint In May 2015, Aytu entered into and closed on an asset purchase agreement with Jazz Pharmaceuticals, Inc. (the “Seller”). Pursuant to the agreement, Aytu purchased assets related to the Seller’s product known as ProstaScint® (capromab pendetide), including certain intellectual property and contracts, and the product approvals, inventory and work in progress (together, the “ProstaScint Business”), and assumed certain of the Seller’s liabilities, including those related to product approvals and the sale and marketing of ProstaScint. The purchase price consisted of the upfront payment of $1.0 million. Aytu also paid an additional $500,000 for the ProstaScint-related product inventory and $227,000 (which represents a portion of certain FDA fees). Aytu also will pay 8% as contingent consideration on its net sales made after October 31, 2017, payable up to a maximum aggregate payment of an additional $2.5 million. The contingent consideration was valued at $664,000 using a discounted cash flow estimate as of the acquisition date. The total fair value consideration for the purchase was $2.4 million. The Company’s allocation on consideration transferred for ProstaScint as of the purchase date of May 20, 2015 is as follows: Fair Value Tangible assets $ 727,000 Intangible assets 1,590,000 Goodwill 74,000 Total assets acquired $ 2,391,000 Included in the intangible assets is developed technology of $790,000, customer contracts of $720,000 and trade names of $80,000, each of which will be amortized over a ten-year period. As of March 31, 2016 the contingent consideration had increased to $699,000 due to accretion. Business Combination—Primsol In October 2015, Aytu entered into and closed on an Asset Purchase Agreement with FSC Laboratories, Inc. (the “Seller”). Pursuant to the agreement, Aytu purchased assets related to the Seller’s product known as Primsol® (trimethoprim solution), including certain intellectual property and contracts, inventory, work in progress and all marketing and sales assets and materials related solely to Primsol (together, the “Primsol Business”), and assumed certain of the Seller’s liabilities, including those related to the sale and marketing of Primsol arising after the closing. Aytu paid $500,000 at closing for the purchase of the Primsol Business and paid an additional $142,000, of which $102,000 went to inventory and $40,000 towards the Primsol Business, for the transfer of the Primsol-related product inventory. We also agreed to pay an additional (a) $500,000 which was paid on April 1, 2016, (b) $500,000 payable no later than June 30, 2016, and (c) $250,000 payable no later than September 30, 2016 (together, the “Installment Payments”). The Company’s allocation on consideration transferred for Primsol as of the purchase date of October 5, 2015 is as follows: Fair Value Tangible assets $ 182,000 Intangible assets 1,470,000 Goodwill 147,000 Total assets acquired $ 1,799,000 Included in tangible assets is $102,000 of inventory and $80,000 of work-in-process inventory. Included in the intangible assets is developed technology of $520,000, customer contracts of $810,000 and trade names of $140,000, each of which will be amortized over a six-year period. As of March 31, 2016, the accrued payable adjusted for the present value was $1,155,000. Adoption of Newly Issued Accounting Pronouncements In September 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-16, “Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments,” which requires that an acquirer recognize adjustments to estimated amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments require that the acquirer record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the estimated amounts, calculated as if the accounting had been completed at the acquisition date. The amendments also require an entity to present separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the estimated amounts had been recognized as of the acquisition date. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2015 and early adoption is permitted. As of March 31, 2016, the Company has early adopted this standard. In April 2015, the FASB issued ASU 2015-03, “Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs” to simplify the presentation of debt issuance costs. The amendments in the update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct reduction of the carrying amount of the debt. Recognition and measurement of debt issuance costs were not affected by this amendment. In August 2015, FASB issued ASU 2015-15, “Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements — Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting” which clarified that the SEC would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement. The amendments are effective for financial statements issued for fiscal years beginning after December 15, 2015. During the quarter ended September 30, 2016, the Company early adopted this standard and recorded debt issuance costs as a debt discount. There was no impact related to this adoption as the Company did not have any debt issuance costs prior to adoption. In November 2015, the FASB issued ASU No. 2015-17 regarding ASC Topic 470 "Income Taxes: Balance Sheet Classification of Deferred Taxes." The amendments in ASU 2015-17 eliminate the requirement to bifurcate deferred taxes between current and non-current on the balance sheet and requires that deferred tax liabilities and assets be classified as noncurrent on the balance sheet. The amendments for ASU-2015-17 can be applied retrospectively or prospectively and early adoption is permitted. Aytu early adopted ASU 2015-17 and there was no material impact on its financial statements.
New Accounting Pronouncements, Policy [Policy Text Block]	Adoption of Newly Issued Accounting Pronouncements In September 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-16, “Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments,” which requires that an acquirer recognize adjustments to estimated amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments require that the acquirer record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the estimated amounts, calculated as if the accounting had been completed at the acquisition date. The amendments also require an entity to present separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the estimated amounts had been recognized as of the acquisition date. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2015 and early adoption is permitted. As of March 31, 2016, the Company has early adopted this standard. In April 2015, the FASB issued ASU 2015-03, “Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs” to simplify the presentation of debt issuance costs. The amendments in the update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct reduction of the carrying amount of the debt. Recognition and measurement of debt issuance costs were not affected by this amendment. In August 2015, FASB issued ASU 2015-15, “Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements — Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting” which clarified that the SEC would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement. The amendments are effective for financial statements issued for fiscal years beginning after December 15, 2015. During the quarter ended September 30, 2016, the Company early adopted this standard and recorded debt issuance costs as a debt discount. There was no impact related to this adoption as the Company did not have any debt issuance costs prior to adoption. In November 2015, the FASB issued ASU No. 2015-17 regarding ASC Topic 470 "Income Taxes: Balance Sheet Classification of Deferred Taxes." The amendments in ASU 2015-17 eliminate the requirement to bifurcate deferred taxes between current and non-current on the balance sheet and requires that deferred tax liabilities and assets be classified as noncurrent on the balance sheet. The amendments for ASU-2015-17 can be applied retrospectively or prospectively and early adoption is permitted. Aytu early adopted ASU 2015-17 and there was no material impact on its financial statements. Recently Issued Accounting Pronouncements, Not Adopted as of March 31, 2016 In March 2016, the FASB issued Accounting Standards Update No. 2016-09, “Compensation –Stock Compensation (Topic 718): Improvements to Employee Share Based Payment Accounting”. The standard includes multiple provisions intended to simplify various aspects of the accounting for share based payments. The amendments are expected to significantly impact net income, EPS, and the statement of cash flows. Implementation and administration may present challenges to companies with significant share based payment activities. The amendments are effective for public entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. The Company is currently evaluating the impact of this standard on its financial statements. In February 2016, the FASB issued Accounting Standards Update 2016-02, “Leases (Topic 842)”. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact of its pending adoption of this standard on its financial statements. In January 2016, the FASB issued ASU 2016-01, “Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities,” which requires that all equity investments be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under the equity method of accounting or those that result in consolidation of the investee). The amendments in this update also require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. In addition, the amendments in this update eliminate the requirement to disclose the fair value of financial instruments measured at amortized cost for entities that are not public business entities and the requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet for public business entities. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2017. Early adoption is not permitted. The Company is currently evaluating the impact of this standard on its financial statements. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” ASU 2015-11 clarifies that inventory should be held at the lower of cost or net realizable value. Net realizable value is defined as the estimated selling price, less the estimated costs to complete, dispose and transport such inventory. ASU 2015-11 will be effective for fiscal years and interim periods beginning after December 15, 2016. ASU 2015-11 is required to be applied prospectively and early adoption is permitted. The adoption of ASU 2015-11 is not expected to have a material impact on the Company’s financial position or results of operations. In August 2014, the FASB issued ASU 2014-15, “Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods ending after December 15, 2016, with early adoption permitted. The Company is evaluating the impact the adoption of ASU 2014-15 will have on its financial statements. In May 2014, the FASB issued ASU 2014-09 regarding ASC Topic 606, “Revenue from Contracts with Customers”. The standard provides principles for recognizing revenue for the transfer of promised goods or services to customers with the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date, which deferred the effective date of the new revenue standard for periods beginning after December 15, 2017, with early adoption permitted. In March 2016, the FASB issued ASU 2016-08, which addresses principal versus agent considerations. The Company is currently evaluating the effect that the updated standard will have on its financial statements.

Business, Acquisition of Asse22

Business, Acquisition of Assets and Basis of Presentation (Tables)	9 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	The Company’s allocation on consideration transferred for ProstaScint as of the purchase date of May 20, 2015 is as follows: Fair Value Tangible assets $ 727,000 Intangible assets 1,590,000 Goodwill 74,000 Total assets acquired $ 2,391,000 The Company’s allocation on consideration transferred for Primsol as of the purchase date of October 5, 2015 is as follows: Fair Value Tangible assets $ 182,000 Intangible assets 1,470,000 Goodwill 147,000 Total assets acquired $ 1,799,000

Fixed Assets (Tables)

Fixed Assets (Tables)	9 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Fixed assets consist of the following: Estimated As of March 31, As of June 30, Useful Lives in years 2016 2015 Office equipment and furniture 3 - 5 $ 154,000 $ - Lab equipment 3 - 5 90,000 90,000 Leasehold improvements 3 43,000 - Manufacturing equipment 5 7,000 - Less accumulated depreciation and amortization (97,000) (60,000) Fixed assets, net $ 197,000 $ 30,000

Patents (Tables)

Patents (Tables)	9 Months Ended
	Mar. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Patents consist of the following: As of March 31, As of June 30, 2016 2015 Patents $ 880,000 $ 880,000 Less accumulated amortization (304,000) (251,000) Patents, net $ 576,000 $ 629,000

Fair Value Considerations (Tabl

Fair Value Considerations (Tables)	9 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Financial Assets And Liabilities Not Measured At Fair Value On Recurring Basis [Table Text Block]	The following table presents Aytu’s financial liabilities that were accounted for at fair value on a recurring basis as of March 31, 2016, by level within the fair value hierarchy: Fair Value Measurements Using Level 1 Level 2 Level 3 Total March 31, 2016 LIABILITIES Warrant derivative liability $ - $ - $ 66,000 $ 66,000
Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]	Significant assumptions in valuing the warrant derivative liability, based on estimates of the value of Aytu common stock and various factors regarding the warrants, were as follows as of March 31, 2016 and at issuance: March 31, 2016 At Issuance Warrants: Exercise price $ 0.64 $ 1.51 - $1.95 Volatility 75.0 % 75.0 % Equivalent term (years) 4.31 - 4.36 5.0 - 5.11 Risk-free interest rate 1.09% - 1.10 % 1.54% - 1.74 % Potential number of shares 159,000 - 228,000 139,000 - 224,000
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair valued hierarchy: Derivative Instruments Balance as of June 30, 2015 $ - Warrant issuances 103,000 Reclassification of warrant liability to equity upon note conversion (87,000) Change in fair value included in earnings 50,000 Balance as of March 31, 2016 $ 66,000

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments And Contingencies Disclosure [Table Text Block]	Commitments and contingencies are described below and summarized by the following table for the designated fiscal years ending June 30, as of March 31, 2016: Remaining Total 2016 2017 2018 2019 2020 Thereafter Management fee $ 901,000 $ 53,000 $ 212,000 $ 212,000 $ 212,000 $ 212,000 $ - Primsol business 1,250,000 1,000,000 250,000 - - - - Manufacturing agreement 1,000,000 1,000,000 - - - - - Office Lease 351,000 34,000 142,000 145,000 30,000 - - Sponsored research agreement with related party 298,000 18,000 70,000 70,000 70,000 70,000 - $ 3,800,000 $ 2,105,000 $ 674,000 $ 427,000 $ 312,000 $ 282,000 $ -
Schedule of Rent Expense [Table Text Block]	Rent expense for the respective periods is as follows: Three Months Ended March 31, Nine Months Ended March 31, 2016 2015 2016 2015 Rent expense $ 35,000 $ 3,000 $ 86,000 $ 43,000

Equity Instruments (Tables)

Equity Instruments (Tables)	9 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	time of the grant for treasury securities of similar maturity. Aytu has computed the fair value of all options granted during the nine months ended March 31, 2016 using the following assumptions: Expected volatility 75.00 % Risk free interest rate 1.21% - 1.90 % Expected term (years) 3.75 - 6.25 Dividend yield 0 %
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Stock option activity is as follows: Weighted Weighted Average Number of Average Remaining Contractual Options Exercise Price Life in Years Outstanding June 30, 2015 - $ - Granted 3,717,500 $ 1.55 Exercised - $ - Forfeited/Cancelled (50,000) $ 1.51 Outstanding March 31, 2016 3,667,500 $ 1.55 9.55 Exercisable at March 31, 2016 1,477,500 $ 1.51 9.62 Available for grant at March 31, 2016 6,332,500
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]	The following table summarizes stock-based compensation expense for the three and nine months ended March 31, 2016 and for the stock-based compensation expense related to the Luoxis and Vyrix options for the three and nine months ended March 31, 2015: Three Months Ended March 31, Nine Months Ended March 31, 2016 2015 2016 2015 Research and development expenses Stock options $ 38,000 $ 115,000 $ 63,000 $ 323,000 Selling, general and administrative expenses Stock options 258,000 157,000 484,000 427,000 $ 296,000 $ 272,000 $ 547,000 $ 750,000 Unrecognized expense at March 31, 2016 $ 1,554,000 Weighted average remaining years to vest 2.90
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Weighted Weighted Average Number of Average Remaining Contractual Warrants Exercise Price Life in Years Outstanding June 30, 2015 102,613 $ 4.53 2.92 Warrants issued to placement agents for convertible promissory notes 267,052 $ 0.65 Outstanding March 31, 2016 (unaudited) 369,665 $ 1.73 3.78
Schedule of Share-based Payment Award, Warrants, Valuation Assumptions [Table Text Block]	Significant assumptions in valuing the warrant liability related to the placement agent warrants issued during the March 31, 2016 quarter were as follows: Expected volatility 75 % Risk free interest rate 1.36% - 1.37 % Contractual term (years) 4.6 Dividend yield 0 %

Business, Acquisition of Asse28

Business, Acquisition of Assets and Basis of Presentation (Details) - USD ($)	Mar. 31, 2016	Oct. 05, 2015	Jun. 30, 2015	May. 31, 2015	May. 20, 2015
Business Acquisition [Line Items]
Goodwill	$ 221,000		$ 74,000
Prostascint Business [Member]
Business Acquisition [Line Items]
Tangible assets		$ 182,000			$ 727,000
Intangible assets		1,470,000			1,590,000
Goodwill		147,000			74,000
Total assets acquired		$ 1,799,000		$ 2,400,000	$ 2,391,000

Business, Acquisition of Asse29

Business, Acquisition of Assets and Basis of Presentation (Details Textual)	Jun. 08, 2015	Oct. 31, 2015USD ($)	May. 31, 2015USD ($)	Mar. 31, 2016USD ($)	Mar. 31, 2015USD ($)	Oct. 05, 2015USD ($)	May. 20, 2015USD ($)
Business Acquisition [Line Items]
Stockholders' Equity, Reverse Stock Split				On June 8, 2015, in connection with the reincorporation as a Delaware corporation, the Company effected a reverse stock split in which each common stock holder received one share of common stock for every 12.174 shares then outstanding (the “Reverse Stock Split”).
Stockholders' Equity Note, Stock Split, Conversion Ratio	12.174
Payments to Acquire Businesses, Gross				$ 540,000	$ 0
Business Combination, Contingent Consideration, Liability, Total				1,155,000
Developed Technology Rights [Member]
Business Acquisition [Line Items]
Amortization of Intangible Assets				520,000
Trade Names [Member]
Business Acquisition [Line Items]
Amortization of Intangible Assets				140,000
Customer Contracts [Member]
Business Acquisition [Line Items]
Amortization of Intangible Assets				$ 810,000
Prostascint Business [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total			$ 2,400,000			$ 1,799,000	$ 2,391,000
Payments to Acquire Businesses, Gross			1,000,000
Business Combination, Consideration Transferred, Liabilities Incurred			227,000
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Reasons				Aytu also will pay 8% as contingent consideration on its net sales made after October 31, 2017, payable up to a maximum aggregate payment of an additional $2.5 million.
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High			$ 2,500,000
Business Combination Contingent Consideration Percentage			8.00%
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset			$ 664,000	$ 699,000
Business Combination Consideration Transferred Product Inventory			$ 500,000
Jazz Pharmaceuticals Inc [Member] | Prosta Scint [Member] | Maximum [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period				10 years
Jazz Pharmaceuticals Inc [Member] | Prosta Scint [Member] | Developed Technology Rights [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Gross				$ 790,000
Jazz Pharmaceuticals Inc [Member] | Prosta Scint [Member] | Trade Names [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Gross				80,000
Jazz Pharmaceuticals Inc [Member] | Prosta Scint [Member] | Customer Contracts [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Gross				720,000
Primsol Business [Member]
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross		$ 500,000
Business Combination, Consideration Transferred, Liabilities Incurred		142,000
Business Combination Consideration Transferred Inventory		102,000		102,000
Business Combination Consideration Transferred Product Inventory		40,000
Business Combination Consideration Transferred Work In Process Inventory				$ 80,000
Primsol Business [Member] | Maximum [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period				6 years
Primsol Business [Member] | Paid on April 1, 2016 [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred, Liabilities Incurred		500,000
Primsol Business [Member] | No Later Than June 30, 2016 [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred, Liabilities Incurred		500,000
Primsol Business [Member] | No Later Than September 30, 2016 [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred, Liabilities Incurred		$ 250,000

Fixed Assets (Details)

Fixed Assets (Details) - USD ($)	9 Months Ended
	Mar. 31, 2016	Jun. 30, 2015
Property, Plant and Equipment [Line Items]
Less accumulated depreciation and amortization	$ (97,000)	$ (60,000)
Fixed assets, net	196,885	29,706
Office equipment and furniture [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 154,000	0
Office equipment and furniture [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Office equipment and furniture [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 90,000	90,000
Lab equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Lab equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 43,000	0
Estimated useful lives	3 years
Manufacturing equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 7,000	$ 0
Estimated useful lives	5 years

In-Process Research and Devel31

In-Process Research and Development (Details Textual) $ in Millions	Mar. 31, 2016USD ($)
Zertane Patents [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets (Excluding Goodwill)	$ 7.5

Patents (Details)

Patents (Details) - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Indefinite-lived Intangible Assets [Line Items]
Patents, net	$ 575,686	$ 628,776
Patents [Member]
Indefinite-lived Intangible Assets [Line Items]
Patents	880,000	880,000
Less accumulated armortization	(304,000)	(251,000)
Patents, net	$ 576,000	$ 629,000

Patents (Details Textual)

Patents (Details Textual)	9 Months Ended
	Mar. 31, 2016USD ($)
Zertane Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 500,000
Finite-Lived Intangible Assets, Remaining Amortization Period	11 years
ORP [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 380,000
Finite-Lived Intangible Assets, Remaining Amortization Period	15 years

Revenue Recognition (Details Te

Revenue Recognition (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Revenue Recognition [Line Items]
Revenue, Net, Total	$ 647,000	$ 2,000	$ 1,561,000	$ 15,000
License and Maintenance Revenue	21,000	$ 64,000	21,000	$ 64,000
KOREA, REPUBLIC OF | Korean Pharmaceutical Company [Member]
Revenue Recognition [Line Items]
Deferred Revenue	500,000		$ 500,000
Deferred Revenue Recognition Period			10 years	10 years
CANADA | Canadian Based Supplier [Member]
Revenue Recognition [Line Items]
Deferred Revenue	$ 250,000		$ 250,000
Deferred Revenue Recognition Period			7 years	7 years

Fair Value Considerations (Deta

Fair Value Considerations (Details) - USD ($)	Mar. 31, 2016	Aug. 31, 2015	Jun. 30, 2015
LIABILITIES
Warrant derivative liability	$ 66,204	$ 103,000	$ 0
Fair Value, Inputs, Level 1 [Member]
LIABILITIES
Warrant derivative liability	0
Fair Value, Inputs, Level 2 [Member]
LIABILITIES
Warrant derivative liability	0
Fair Value, Inputs, Level 3 [Member]
LIABILITIES
Warrant derivative liability	$ 66,000

Fair Value Considerations (De36

Fair Value Considerations (Details 1)	9 Months Ended
	Mar. 31, 2016$ / sharesshares
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Equivalent term (years)	5 years
Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price | $ / shares	$ 0.64
Volatility	75.00%
Warrant [Member] | Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Equivalent term (years)	4 years 4 months 10 days
Risk-free interest rate	1.10%
Potential number of shares	228,000
Warrant [Member] | Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Equivalent term (years)	4 years 3 months 22 days
Risk-free interest rate	1.09%
Potential number of shares	159,000
Issuance Date [Member] | Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility	75.00%
Issuance Date [Member] | Warrant [Member] | Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price | $ / shares	$ 1.95
Equivalent term (years)	5 years 1 month 10 days
Risk-free interest rate	1.74%
Potential number of shares	224,000
Issuance Date [Member] | Warrant [Member] | Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price | $ / shares	$ 1.51
Equivalent term (years)	5 years
Risk-free interest rate	1.54%
Potential number of shares	139,000

Fair Value Considerations (De37

Fair Value Considerations (Details 2) - Fair Value, Inputs, Level 3 [Member]	9 Months Ended
	Mar. 31, 2016USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of June 30, 2015	$ 0
Warrant issuances	103,000
Reclassification of warrant liability to equity upon note conversion	(87,000)
Change in fair value included in earnings	50,000
Balance as of March 31, 2016	$ 66,000

Commitments and Contingencies38

Commitments and Contingencies (Details)	Mar. 31, 2016USD ($)
Unrecorded Unconditional Purchase Obligation [Line Items]
Total	$ 3,800,000
Remaining 2,016	2,105,000
2,017	674,000
2,018	427,000
2,019	312,000
2,020	282,000
Thereafter	0
Management Fees [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Total	901,000
Remaining 2,016	53,000
2,017	212,000
2,018	212,000
2,019	212,000
2,020	212,000
Thereafter	0
Primsol Business [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Total	1,250,000
Remaining 2,016	1,000,000
2,017	250,000
2,018	0
2,019	0
2,020	0
Thereafter	0
Manufacturing Agreement [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Total	1,000,000
Remaining 2,016	1,000,000
2,017	0
2,018	0
2,019	0
2,020	0
Thereafter	0
Office Lease [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Total	351,000
Remaining 2,016	34,000
2,017	142,000
2,018	145,000
2,019	30,000
2,020	0
Thereafter	0
Sponsored research agreement with related party [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Total	298,000
Remaining 2,016	18,000
2,017	70,000
2,018	70,000
2,019	70,000
2,020	70,000
Thereafter	$ 0

Commitments and Contingencies39

Commitments and Contingencies (Details 1) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Commitments And Contingencies Rent Expense [Line Items]
Rent expense	$ 35,000	$ 3,000	$ 86,000	$ 43,000

Commitments and Contingencies40

Commitments and Contingencies (Details Textual) - USD ($)	1 Months Ended				9 Months Ended
	Apr. 30, 2016	Sep. 30, 2015	Jul. 31, 2015	Jun. 30, 2015	Mar. 31, 2016
Unrecorded Unconditional Purchase Obligation [Line Items]
Management Fee Payable Per Month			$ 18,000
Contractual Obligation, Total					$ 3,800,000
COLORADO [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Operating Leases Monthly Base Rent Initial Year		$ 9,000
Lessee Leasing Arrangements, Operating Leases, Term of Contract		37 months
Operating Leases, Rent Expense		$ 318,000
NORTH CAROLINA [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Operating Leases Monthly Base Rent Initial Year				$ 3,000
Lessee Leasing Arrangements, Operating Leases, Term of Contract				37 months
Operating Leases, Rent Expense				$ 112,000
Sponsored research agreement with related party [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Contractual Obligation, Total					$ 298,000
Agreement Termination Notice Period					30 days
Manufacturing Agreement [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Contractual Obligation, Total					$ 1,000,000
Payment Of Contractual Obligations	$ 500,000

Convertible Promissory Notes (D

Convertible Promissory Notes (Details Textual) - USD ($)	Feb. 10, 2016	Feb. 10, 2015	May. 05, 2016	Mar. 31, 2016	Mar. 31, 2015	Jan. 20, 2016	Aug. 31, 2015	Jun. 30, 2015
Debt Conversion [Line Items]
Debt Instrument, Face Amount							$ 5,200,000
Unamortized Debt Issuance Expense							401,000
Derivative Liability, Noncurrent				$ 66,204			$ 103,000	$ 0
Proceeds from Convertible Debt				$ 5,175,000	$ 0
Class Of Warrant Term				5 years
Debt Issuance Cost				$ 20,000
Placement Agents Cash Fee Percentage				8.00%
Debt Instrument, Convertible, Beneficial Conversion Feature				$ 4,943,073	$ 4,943,073
Warrants Issued to Purchase of common stock	267,052
Warrants Exercise Price Per share	$ 0.65
Warrants Exercisable Term	5 years
Debt Instrument Conversion Premium Percentage				10.00%
Convertible Debt [Member]
Debt Conversion [Line Items]
Interest Payable, Current				$ 66,000
Convertible Promissory Notes [Member]
Debt Conversion [Line Items]
Debt Instrument Interest Rate For Extension Period1				2.00%
Debt Instrument, Term				18 months
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum				8.00%
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Maximum				12.00%
Convertible Notes Equal To Percentage Of Common Stock				120.00%
Debt Instrument Conversion Share Price				$ 4.63
Debt Instrument, Convertible, Terms of Conversion Feature				The Notes are convertible at any time at the noteholder’s discretion into that number of shares of Aytu common stock equal to 120% of the number of shares of common stock calculated by dividing the then outstanding principal and accrued interest by $4.63. A holder of Notes will be obligated to convert on the terms of Aytu’s next public offering of its stock resulting in gross proceeds of at least $5,000,000 (excluding indebtedness converted in such financing) prior to the maturity date of the Notes (a “Qualified Financing”). The principal and accrued interest under the Notes will automatically convert into a number of shares of such equity securities of the Company sold in the Qualified Financing equal to 120% of the principal and accrued interest under such Note divided by the lesser of (i) the lowest price paid by an investor in the Qualified Financing or (ii) $4.63. In the event that Aytu sells equity securities to investors at any time while the Notes are outstanding in a financing transaction that is not a Qualified Financing, then the noteholders will have the option to convert in whole the outstanding principal and accrued interest as of the closing of such financing into a number of shares of Aytu capital stock in an amount equal to 120% of the number of such shares calculated by dividing the outstanding principal and accrued interest by the lesser of (i) the lowest cash price per share paid by purchasers of shares in such financing, or (ii) $4.63.
Debt Issuance Cost				$ 0
Debt Conversion, Original Debt, Amount		$ 4,125,000
Debt Conversion Accrued Interest Amount		$ 143,000
Debt Conversion, Converted Instrument, Shares Issued		7,879,096
Long-term Debt, Gross				1,050,000
Debt Instrument, Convertible, Beneficial Conversion Feature	$ 3,900,000			1,040,000
Debt Instrument, Unamortized Discount				10,000
Debt Instrument, Convertible, Conversion Price						$ 0.65
Convertible Promissory Notes [Member] | Placement Agent [Member]
Debt Conversion [Line Items]
Debt Conversion, Converted Instrument, Shares Issued			270,772
Convertible Promissory Notes [Member] | Minimum [Member]
Debt Conversion [Line Items]
Proceeds from Convertible Debt				$ 5,000,000
Convertible Promissory Notes [Member] | Promissory Notes Payable One [Member]
Debt Conversion [Line Items]
Debt Instrument, Maturity Date				Jan. 22, 2017
Convertible Promissory Notes [Member] | Promissory Notes Payable Two [Member]
Debt Conversion [Line Items]
Debt Instrument, Maturity Date				Feb. 11, 2017
Convertible Promissory Notes [Member] | Promissory Notes Payable Three [Member]
Debt Conversion [Line Items]
Debt Instrument, Maturity Date				Feb. 28, 2017

Common Stock (Details Textual)

Common Stock (Details Textual) - $ / shares	Mar. 31, 2016	Jun. 30, 2015
Common Stock [Line Items]
Common Stock, Shares Authorized	300,000,000	300,000,000
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	50,000,000	50,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized, Amendment	100,000,000
Preferred Stock, Shares Authorized, Amendment	10,000,000
Common Stock, Shares, Outstanding	22,446,481	14,259,681

Equity Instruments (Details)

Equity Instruments (Details) - Luoxis Diagnostics [Member]	9 Months Ended
	Mar. 31, 2016
Assumptions Used To Determine Fair Value Options [Line Items]
Expected volatility	75.00%
Risk free interest rate, Minimum	1.21%
Risk free interest rate, Maximum	1.90%
Dividend yield	0.00%
Minimum [Member]
Assumptions Used To Determine Fair Value Options [Line Items]
Expected term (years)	3 years 9 months
Maximum [Member]
Assumptions Used To Determine Fair Value Options [Line Items]
Expected term (years)	6 years 3 months

Equity Instruments (Details 1)

Equity Instruments (Details 1) - Luoxis Diagnostics [Member]	9 Months Ended
	Mar. 31, 2016$ / sharesshares
Number of Options
Number of Options, Beginning Balance	0
Number of Options, Granted	3,717,500
Number of Options, Exercised	0
Number of Options, Forfeited/Cancelled	(50,000)
Number of Options, Ending Balance	3,667,500
Exercisable at March 31, 2016	1,477,500
Available for grant at March 31, 2016	6,332,500
Weighted Average Exercise Price
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 0
Weighted Average Exercise Price, Granted | $ / shares	1.55
Weighted Average Exercise Price, Exercised | $ / shares	0
Weighted Average Exercise Price, Forfeited/Cancelled | $ / shares	1.51
Weighted Average Exercise Price, Ending Balance | $ / shares	1.55
Weighted average exercise price, Exercisable at March 31, 2016 | $ / shares	$ 1.51
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Life, Outstanding (in years)	9 years 6 months 18 days
Weighted Average Remaining Contractual Life, Excercisable (in years)	9 years 7 months 13 days

Equity Instruments (Details 2)

Equity Instruments (Details 2) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized expense at March 31, 2016	$ 1,554,000
Weighted average remaining years to vest (in years)	2 years 10 months 24 days
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 296,000	$ 272,000	$ 547,000	$ 750,000
Research and Development Expense [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	38,000	115,000	63,000	323,000
General and Administrative Expense [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 258,000	$ 157,000	$ 484,000	$ 427,000

Equity Instruments (Details 3)

Equity Instruments (Details 3) - $ / shares	9 Months Ended	12 Months Ended
	Mar. 31, 2016	Jun. 30, 2015
Number of Warrants Outstanding
Number of Warrants Outstanding, Beginning Balance	102,613
Warrants issued to placement agents for convertible promissory notes	267,052
Number of Warrants Outstanding, Ending Balance	369,665	102,613
Warrants, Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 4.53
Warrants issued to placement agents for convertible promissory notes	0.65
Weighted Average Exercise Price, Outstanding Ending Balance	$ 1.73	$ 4.53
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Life, Warrants Outstanding (in years)	3 years 9 months 11 days	2 years 11 months 1 day

Equity Instruments (Details 4)

Equity Instruments (Details 4) - Warrant [Member]	3 Months Ended
	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	75.00%
Risk free interest rate, Minimum	1.36%
Risk free interest rate, Maximum	1.37%
Expected term (years)	4 years 7 months 6 days
Dividend yield	0.00%

Equity Instruments (Details Tex

Equity Instruments (Details Textual) - USD ($)	9 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Jun. 30, 2015	Jun. 02, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	1,718,828,000,000
Conversion of Stock, Description	The number of shares of Company stock that these warrants will convert into is equal to 8% of the gross number of shares of the Company stock issuable upon conversion of the Notes issued to investors introduced to the Company by the private placement agents pursuant to the private placement memorandum. The exercise price will be the conversion price per share at which the first outstanding Note converts into Company common stock. The warrants have a term of five years from August 31, 2015 due to the conversion setting the price of these warrants (see Note 8).
Fair Value Assumptions, Expected Term	5 years
Share Based Compensation Share Warrants Issued on Convertible Promisory Notes	267,052
Share Based Compensation Share Warrants Issued on Convertible Promisory Notes, Weighted Average Exercise Price	$ 0.65
Adjustment To Additional Capital Issuance Of Warrants Related To Convertible Promissory Note	$ 87,000	$ 0
Ampio Board And Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures, Total	1,447,500
Ampio [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	1,300,000
2013 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense			$ 27,000
Luoxis 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total			422,000
Reversal Of Allocated Share Based Compensation Expense	$ 433,000
2015 Stock Option and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance				10,000,000
Vyrix 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total			$ 189,000

Related Party Transactions (Det

Related Party Transactions (Details Textual) - USD ($)	1 Months Ended				9 Months Ended	12 Months Ended
	Apr. 16, 2015	Mar. 31, 2014	Nov. 30, 2013	Jun. 30, 2013	Mar. 31, 2016	Jun. 30, 2014	Aug. 31, 2015	Jun. 30, 2015
Related Party Transaction [Line Items]
Common Stock, Shares, Issued					22,446,481			14,259,681
Debt Instrument, Face Amount							$ 5,200,000
Ampio [Member]
Related Party Transaction [Line Items]
Common Stock, Shares, Issued	4,761,787
Ampio [Member] | Senior Management [Member]
Related Party Transaction [Line Items]
Convertible Notes Payable					$ 275,000
Ampio [Member] | Second Installment [Member] | Scenario, Plan [Member]
Related Party Transaction [Line Items]
Property Subject to or Available for Operating Lease, Net, Total		$ 615,000
Ampio [Member] | Second Installment [Member] | After Amendment [Member] | Scenario, Plan [Member]
Related Party Transaction [Line Items]
Operating Lease Monthly Rental Payment				$ 6,000
Ampio [Member] | First Installment [Member] | Scenario, Plan [Member]
Related Party Transaction [Line Items]
Prepaid Expenses Amortization Period		60 months 15 days
Lease Agreements Maturity Period					March 2,019
Ampio [Member] | Ampio Loan Agreement [Member]
Related Party Transaction [Line Items]
Cash Advances For Short Term Loans			$ 500,000
Long-term Line of Credit		$ 3,000,000	$ 3,000,000
Debt Instrument, Term		1 year	1 year
Ampio [Member] | Ampio Loan Agreement [Member] | Vyrix Pharmaceuticals Inc [Member]
Related Party Transaction [Line Items]
Line of Credit Facility, Remaining Borrowing Capacity	$ 4,000,000					$ 1,600,000
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum						3.11%
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Maximum						3.32%
Ampio [Member] | Ampio Loan Agreement [Member] | Luoxis Diagnostics [Member]
Related Party Transaction [Line Items]
Line of Credit Facility, Remaining Borrowing Capacity	8,000,000					$ 3,000,000
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum						3.11%
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Maximum						3.32%
Ampio [Member] | Promissory Note [Member]
Related Party Transaction [Line Items]
Debt Instrument, Face Amount	10,000,000
Ampio [Member] | Promissory Note [Member] | Vyrix Pharmaceuticals Inc [Member]
Related Party Transaction [Line Items]
Debt Instrument, Decrease, Forgiveness	4,000,000
Ampio [Member] | Promissory Note [Member] | Luoxis Diagnostics [Member]
Related Party Transaction [Line Items]
Debt Instrument, Decrease, Forgiveness	$ 8,000,000

Subsequent Events (Details Text

Subsequent Events (Details Textual)

Feb. 10, 2015USD ($)shares

May. 05, 2016USD ($)$ / sharesshares

May. 02, 2016USD ($)$ / sharesshares

Apr. 30, 2016USD ($)$ / sharesshares

Apr. 28, 2016USD ($)shares

Apr. 28, 2016CADCAD / sharesshares

Apr. 22, 2016USD ($)

Mar. 31, 2016$ / sharesshares

Jan. 01, 2017USD ($)

Sep. 05, 2016USD ($)

May. 06, 2016$ / sharesshares

Jan. 20, 2016$ / shares

Jun. 30, 2015$ / sharesshares

Subsequent Event [Line Items]

Payments for Fees | $

$ 2,000,000

Common Stock, Par or Stated Value Per Share | $ / shares

$ 0.0001

$ 0.0001

Common Stock, Shares, Outstanding | shares

22,446,481

14,259,681

Convertible Promissory Notes [Member]

Subsequent Event [Line Items]

Debt Instrument, Convertible, Conversion Price | $ / shares

$ 0.65

Convertible Notes Equal To Percentage Of Common Stock

120.00%

Debt Conversion, Original Debt, Amount | $

$ 4,125,000

Debt Conversion, Converted Instrument, Shares Issued | shares

7,879,096

Common Stock, Shares, Outstanding | shares

26,106,459

Joseph Gunnar Co [Member]

Subsequent Event [Line Items]

Class Of Warrant Or Right Exercisable Period

5 years

Placement Agent [Member] | Convertible Promissory Notes [Member]

Subsequent Event [Line Items]

Class Of Warrant Or Right Exercisable Period

5 years

Debt Conversion, Converted Instrument, Shares Issued | shares

270,772

Subsequent Event [Member]

Subsequent Event [Line Items]

Proceeds from Issuance of Common Stock | $

$ 6,700,000

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 0.64

Common Stock, Shares, Outstanding | shares

44,856,459

Class of Warrant or Right, Outstanding | shares

30,279,665

Subsequent Event [Member] | Convertible Promissory Notes [Member]

Subsequent Event [Line Items]

Share Price | $ / shares

$ 0.40

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

3,659,978

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 0.50

Debt Conversion, Converted Instrument, Shares Issued | shares

3,659,978

Subsequent Event [Member] | Over-Allotment Option [Member]

Subsequent Event [Line Items]

Class Of Warrant Or Right Warrants Exercised | shares

2,049,250

Subsequent Event [Member] | Private Placement [Member]

Subsequent Event [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

1,312,500

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 0.50

Class Of Warrant Or Righst Exercisable Term

5 years

Public Offering Warrants To Be Placement Agents, Percentage

7.00%

Subsequent Event [Member] | Warrant [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, New Issues | shares

2,812,500

Subsequent Event [Member] | Option on Securities [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, New Issues | shares

2,812,500

Subsequent Event [Member] | License And Supply Agreement [Member]

Subsequent Event [Line Items]

Number of Shares Purchased | shares

12,245,411

12,245,411

Value of Shares Purchased

$ 2,000,000

CAD 2,534,800

License and supply agreement, Description

Pursuant to the agreement, Aytu will pay Acerus a supply price per unit of the greater of 115% of Acerus’ cost of goods sold for Natesto, not to exceed a fixed ceiling price and (ii) 10% of the net selling price for the first year of the agreement that increases to 16% in the second and 25% in the third year of the agreement and remains constant after that. Upon the expiration or invalidation of the last-to-expire (or be invalidated) Acerus patent covered by the agreement, the supply price will be reduced to an amount equal to the sum of (A) 115% of Acerus’ cost of goods sold (but not to exceed the fixed ceiling price) and (B) 50% of the difference between the supply price and 115% of Acerus’ cost of goods sold (but not to exceed the fixed ceiling price); provided that the supply price will not be reduced to an amount lower than 115% of Acerus’ cost of goods sold (but no to exceed the fixed ceiling price).

Pursuant to the agreement, Aytu will pay Acerus a supply price per unit of the greater of 115% of Acerus cost of goods sold for Natesto, not to exceed a fixed ceiling price and (ii) 10% of the net selling price for the first year of the agreement that increases to 16% in the second year and 25% in the third year of the agreement and remains constant after that. Upon the expiration or invalidation of the last-to-expire (or be invalidated) Acerus patent covered by the agreement, the supply price will be reduced to an amount equal to the sum of (A) 115% of Acerus cost of goods sold (but not to exceed the fixed ceiling price) and (B) 50% of the difference between the supply price and 115% of Acerus cost of goods sold (but not to exceed the fixed ceiling price); provided that the supply price will not be reduced to an amount lower than 115% of Acerus cost of goods sold (but no to exceed the fixed ceiling price).

Pursuant to the agreement, Aytu will pay Acerus a supply price per unit of the greater of 115% of Acerus cost of goods sold for Natesto, not to exceed a fixed ceiling price and (ii) 10% of the net selling price for the first year of the agreement that increases to 16% in the second year and 25% in the third year of the agreement and remains constant after that. Upon the expiration or invalidation of the last-to-expire (or be invalidated) Acerus patent covered by the agreement, the supply price will be reduced to an amount equal to the sum of (A) 115% of Acerus cost of goods sold (but not to exceed the fixed ceiling price) and (B) 50% of the difference between the supply price and 115% of Acerus cost of goods sold (but not to exceed the fixed ceiling price); provided that the supply price will not be reduced to an amount lower than 115% of Acerus cost of goods sold (but no to exceed the fixed ceiling price).

Shares Purchased, Price Per Share | CAD / shares

CAD 0.207

Subsequent Event [Member] | License And Supply Agreement [Member] | Second Upfront [Member]

Subsequent Event [Line Items]

Accrued Additional Upfront Fees | $

$ 2,000,000

Subsequent Event [Member] | License And Supply Agreement [Member] | Third Upfront [Member]

Subsequent Event [Line Items]

Accrued Additional Upfront Fees | $

$ 4,000,000

Subsequent Event [Member] | License And Supply Agreement [Member] | First Milestone [Member]

Subsequent Event [Line Items]

One Time Non-Refundable Payments | $

$ 2,500,000

Sales Revenue Target | $

25,000,000

Subsequent Event [Member] | License And Supply Agreement [Member] | Second Milestone [Member]

Subsequent Event [Line Items]

One Time Non-Refundable Payments | $

5,000,000

Sales Revenue Target | $

50,000,000

Subsequent Event [Member] | License And Supply Agreement [Member] | Third Milestone [Member]

Subsequent Event [Line Items]

One Time Non-Refundable Payments | $

7,500,000

Sales Revenue Target | $

75,000,000

Subsequent Event [Member] | License And Supply Agreement [Member] | Forth Milestone [Member]

Subsequent Event [Line Items]

One Time Non-Refundable Payments | $

10,000,000

Sales Revenue Target | $

100,000,000

Subsequent Event [Member] | License And Supply Agreement [Member] | Fifth Milestone [Member]

Subsequent Event [Line Items]

One Time Non-Refundable Payments | $

12,500,000

Sales Revenue Target | $

$ 125,000,000

Subsequent Event [Member] | Joseph Gunnar Co [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, New Issues | shares

18,750,000

Common Stock, Par or Stated Value Per Share | $ / shares

$ 0.0001

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares

18,750,000

Shares Issued, Price Per Share | $ / shares

$ 0.40

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 0.50

Subsequent Event [Member] | Placement Agent [Member] | Convertible Promissory Notes [Member]

Subsequent Event [Line Items]

Debt Instrument, Convertible, Conversion Price | $ / shares

$ 0.40

Shares Issuable On Convertible Notes As Percentage To Shares Outstanding Subsequent

8.00%

Debt Conversion, Converted Instrument, Shares Issued | shares

270,772

Subsequent Event [Member] | Principal Amount [Member] | Convertible Promissory Notes [Member]

Subsequent Event [Line Items]

Debt Conversion, Original Debt, Amount | $

$ 1,050,000

Subsequent Event [Member] | Accrued Interest [Member] | Convertible Promissory Notes [Member]

Subsequent Event [Line Items]

Debt Conversion, Original Debt, Amount | $

$ 78,000

Subsequent Event [Member] | Maximum [Member] | Convertible Promissory Notes [Member]

Subsequent Event [Line Items]

Convertible Notes Equal To Percentage Of Common Stock

130.00%

Subsequent Event [Member] | Minimum [Member] | Convertible Promissory Notes [Member]

Subsequent Event [Line Items]

Convertible Notes Equal To Percentage Of Common Stock

120.00%

Subsequent Event [Member] | Director [Member]

Subsequent Event [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares

100,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares

$ 0.56